Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2018, Article ID 7978958, 5 pages
https://doi.org/10.1155/2018/7978958
Review Article

Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma

1Department of Urology, Loma Linda University, 11234 Anderson Street Room A-560, Loma Linda, CA 92374, USA
2University of Southern California Institute of Urology, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA

Correspondence should be addressed to Brian Hu; moc.liamg@08uh.nairb

Received 2 October 2017; Accepted 13 December 2017; Published 1 February 2018

Academic Editor: Aditya Bagrodia

Copyright © 2018 Brian Hu and Siamak Daneshmand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Beyer, P. Albers, R. Altena et al., “Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer,” Annals of Oncology, vol. 24, no. 4, pp. 878–888, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. K. Zagars, M. T. Ballo, A. K. Lee, and S. S. Strom, “Mortality after cure of testicular seminoma,” Journal of Clinical Oncology, vol. 22, no. 4, pp. 640–647, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. G. E. Hanks, T. Peters, and J. Owen, “Seminoma of the testis: long-term beneficial and deleterious results of radiation,” International Journal of Radiation Oncology, Biology, Physics, vol. 24, no. 5, pp. 913–919, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Daneshmand, P. Albers, S. D. Fossa et al., “Contemporary management of postchemotherapy testis cancer,” European Urology, vol. 62, no. 5, pp. 867–876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Yadav, “Retroperitoneal lymph node dissection: an update in testicular malignancies,” Clinical and Translational Oncology, vol. 19, no. 7, pp. 793–798, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Syan-Bhanvadia, S. T. Bazargani, T. G. Clifford, J. Cai, G. Miranda, and S. Daneshmand, “Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity,” European Urology, vol. 72, no. 5, pp. 814–820, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kunit and G. Janetschek, “Minimally invasive retroperitoneal lymphadenectomy: current status,” Urologic Clinics of North America, vol. 42, no. 3, pp. 321–329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Warszawski and M. Schmucking, “Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy,” Scandinavian Journal of Urology and Nephrology, vol. 31, no. 4, pp. 355–359, 1997. View at Publisher · View at Google Scholar
  9. F. L. Greene, D. L. Page, and I. D. Fleming, AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010.
  10. Z. Mezvrishvili and L. Managadze, “Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma,” International Urology and Nephrology, vol. 38, no. 3-4, pp. 615–619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Hu, S. Shah, S. Shojaei, and S. Daneshmand, “Retroperitoneal lymph node dissection as first-line treatment of node-positive seminoma,” Clinical Genitourinary Cancer, vol. 13, no. 4, pp. e265–e269, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Kim, S. Syan-Bhanvadia, H. Djaladat et al., “Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor,” Urology, vol. 80, no. 4, pp. 941–945, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Lusch, L. Gerbaulet, C. Winter, and P. Albers, “Primary retroperitoneal lymph node dissection (RPLND) in stage IIA/B seminoma patients without adjuvant treatment: a phase II trial (PRIMETEST),” Journal of Urology, vol. 197, no. 4, pp. e1044–e1045, 2017. View at Publisher · View at Google Scholar
  14. ClinicalTrials.gov, Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma, National Library of Medicine, Bethesda, MD, USA, 2017, http://www.clinicaltrials.gov/show/NCTNCT02537548.
  15. ClinicalTrials.gov, Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST), National Library of Medicine, Bethesda, MD, USA, 2017, http://www.clinicaltrials.gov/show/NCTNCT02797626.
  16. J. Baniel, R. S. Foster, R. G. Rowland, R. Bihrle, and J. P. Donohue, “Complications of primary retroperitoneal lymph node dissection,” Journal of Urology, vol. 152, no. 2, pp. 424–427, 1994. View at Publisher · View at Google Scholar
  17. A. Heidenreich, P. Albers, M. Hartmann et al., “Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group,” Journal of Urology, vol. 169, no. 5, pp. 1710–1714, 2003. View at Publisher · View at Google Scholar · View at Scopus